Company intelligence / Profile preview

EpiVax

Providence, Rhode Island, United Statesepivax.com ↗

Ownership: Private
Development stage: Commercial

Overview

EpiVax is a pioneering computational immunology company specializing in the prediction and modulation of immune responses to biologic drugs and vaccines. It has developed proprietary tools such as EpiMatrix® for vaccine design and ISPRI™ for reducing unwanted immunogenicity. The company has contributed to the development of novel vaccines—including a COVID‑19 candidate—and collaborates extensively with pharmaceutical companies, academia, and regulatory agencies. Its technologies are widely used across the industry to improve safety and efficacy profiles of new therapeutics.

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Peptide vaccinesProtein therapeuticsComputational immunology platformsBiologics (focus on immunogenicity assessment and vaccine design)
Industry: Drug Discovery Services

Partnerships

Ipsen (botulinum toxin engineering)University of Georgia & Immunomic Therapeutics (COVID-19 vaccine)frequent collaborations with pharma companies for immunogenicity assessment

Beyond the preview

Go deeper on EpiVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiVax.

Explore the full profile